Research progress of XPO1 inhibitor selinexor in the treatment of acute myeloid leukemia
顾家琦 1邓建川2
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 重庆医科大学研究生院,重庆 400010
2. 重庆医科大学附属第二医院血液科,重庆 400010
折叠
摘要
急性髓系白血病(AML)是以骨髓和血液中的骨髓原始细胞克隆性增殖为特征的血液系统恶性肿瘤.尽管研究者们不断提出新的治疗方案,但患者的总体预后并没有产生显著改善.核输出蛋白1(nuclear export protein 1,XPO1)抑制剂通过抑制导致肿瘤发生的关键物质穿过癌细胞核膜而在癌症中发挥重要作用,其能促进AML细胞的细胞周期停滞和凋亡,与其他靶向药物或化疗方案组合能发挥广泛的抗癌作用并有较好的安全性.该文主要对XPO1抑制剂塞利尼索治疗AML的研究进展进行综述.
Abstract
Acute myeloid leukemia(AML)is a hematological malignancy characterized by clonal prolif-eration of bone marrow progenitor cells in bone marrow and blood.Although researchers have continuously proposed new treatment options,the overall prognosis of patients has not improved significantly.The nuclear export protein 1(XPO1)inhibitor plays an important role in cancer by inhibiting the key substances leading to tumorigenesis through the nuclear membrane of cancer cells.It can promote cell cycle arrest and apoptosis in AML cells,and has a wide range of anti-cancer effects and good safety in combination with other targeted drugs or chemotherapy regimens.This article mainly reviewed the research progress of XPO1 inhibitor selin-eror in the treatment of AML.
关键词
急性髓系白血病/塞利尼索/核输出蛋白抑制剂/核输出蛋白1/综述
Key words
Acute myeloid leukemia/Selinexor/Nuclear export protein inhibitor/Nuclear export protein 1/Review
维普
万方数据